TNF and obesity disorder: In an HFD model of obesity in Swiss mice, the administration of CGS21680, an A2aAR agonist, improved glucose homeostasis, as determined by insulin tolerance test, and reduced inflammatory markers such as tumor necrosis factor alpha (TNFα) systemically and in the visceral adipose tissue [82].